studies have shown that post-prostatectomy nadir USPSA levels between 0.01 and 0.04 ng/mL were independent predictors of BCR after RP; though, the sensitivity of the method was low. [8] [9] [10] [11] [12] On the other hand, USPSA could increase the anxiety of patients who may have clinically meaningless rises of USPSA. 13 Ultrasensitive PSA could aid clinicians to tailor the follow-up of patients according to their USPSA-based risk stratification and identify those who would benefit from adjuvant therapy. Aim of the present study was to determine the usefulness of the USPSA levels for predicting BCR outcome after robot-assisted radical prostatectomy (RARP) so as to plan postoperative management such as timing of imaging and salvage treatment. In addition, we recorded possible correlations of the examined parameters with BCR, and a prognostic model was developed.
| MATERIAL S AND ME THODS

| Study population
After obtaining institutional approval, we retrospectively reviewed with PSA value = 0.05 ng/mL (since this value was often used in the database input for non-ultrasensitive values) were excluded.
| Biochemical recurrence
Biochemical recurrence was defined as two consecutive PSA rises of ≥0.2 ng/mL at least 3 months after surgery. 4 Salvage radiotherapy (RT) to the prostatic fossa is recommended at a rising PSA below 0.5 ng/mL. 4 Therefore, we also aimed at developing a predictive model for BCR with PSA rise over 0.5 ng/mL.
| Statistical analysis
The 
| RE SULTS
| Baseline characteristics and differences between BCR and non-BCR groups
Baseline patient's characteristics and the differences between BCR (PSA ≥ 0.2 ng/mL) and non-BCR groups are presented in Table 1 . The variables that were significantly different in Table 1 were included in the regression analysis for the prediction of BCR in the two groups of PSA recurrence: PSA ≥0.2 ng/mL (Table 2 ) and PSA ≥0.5 ng/mL (Table 3) .
| BCR with PSA ≥0.2 ng/mL
The pre-treatment PSA was associated with increased BCR risk when the level was ≥30 ng/mL ( Figure S1 ). Therefore in the prognostic model this value was dichotomized: lower or higher than 30 ng/mL. P = 0.003), and shorter interval since RARP (OR = 0.58, 95% CI = 0.427-0.781, P < 0.001) were independent predictors of BCR (Table 2 ).
The AUC was 0.865 (95% CI = 0.834-0.896) suggesting a high accuracy of the model ( Figure S3 ). In the calibration plots, our model showed a slight underestimation of BCR risk in the intermediate risk patients while it was performing close to the ideal line in the lowand high-risk patients ( Figure S4 ). In the decision curve analysis, our model performed well in most thresholds of probabilities, except the higher ones ( Figure S5 ). Table 3 ).
| BCR
The AUC was 0.834 (95% CI = 0.801-0.868), suggesting a high accuracy of the model ( Figure S6 ). In the calibration plots, our model showed a slight overestimation of BCR risk in the intermediate risk patients while it was performing close to the ideal line in the lowand high-risk patients ( Figure S7 ). In the decision curve analysis, our model performed well in most thresholds of probabilities ( Figure S8 ).
| D ISCUSS I ON
The prognostic ability of USPSA has not been thoroughly evaluated.
To the best of our knowledge, our study is the first to explore the BCR outcome as defined as a PSA ≥0.2 ng/mL of men treated by RARP using the USPSA postoperative levels as prognostic factor.
Based on our results, a USPSA of 0.02 ng/mL is associated with a that patients with USPSA nadir levels of >0.01 ng/mL had increased risk of BCR (OR = 3.75, P < 0.001). 14 Vesely et al 15 in a single-institution study of 319 men found that USPSA nadir >0.1 ng/mL and time to nadir <3 months are independent predictors of BCR. Shen et al showed that men with a USPSA nadir <0.01 ng/mL had a 4% BCR rate at 3 years while Eisenberg et al reported that USPSA level ≤0.05 ng/mL was a significant prognostic indicator of BCR-free survival at 5 years. 8, 9 Lepor et al found that AccuPSA™ (a digital single molecule immunoassay) which detects PSA a 1000-fold more sensitively than standard methods, was a significant predictor of BCR-free survival with 62.5% of men with values >3 pg/mL developing BCR at 5 years follow-up. 16 Hong et al using an ultrasensitive radioimmunoassay method, presented 3-year BCR-free survivals of 95.5%, 79.8%, 78.0%, and 41.5% for patients with USPSA levels of <0.001, 0.001-0.02, 0.02-0.05, and ≥0.05 ng/mL, respectively.
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We confirmed the prognostic ability of USPSA in a multivariate model demonstrating a high predictive accuracy of the overall model at 24 months. Not surprisingly, other well-established risk factors, such as Gleason score and positive surgical margin, were also significantly associated with BCR. In the literature, Gleason score is considered the most important prognostic factor of BCR and after RP tertiary Gleason pattern in the prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. 17 Many studies have shown that positive margin is an independent predictor of BCR [18] [19] [20] while others had contradictory results. 21, 22 Patients at high risk of BCR after RP are not reliably identified with the current predictive models. 23 Recent studies have shown that genomic biomarkers are independent predictors of metastasis TA B L E 3 Univariate and multivariate analyses of BCR with PSA ≥0.5 ng/mL in patients with detectable PSA after RP, 24 and they could also discriminate aggressive and non-aggressive tumors. 25 While adjuvant therapy is considered for patients with adverse pathologic features an overtreatment risk of approximately 50% should be kept in mind. [26] [27] [28] In this setting, clinicians should balance between the potential benefits of adjuvant treatment and the potential morbidity of a possible unnecessary intervention. Ultrasensitive PSA could identify the patients who are in high risk of BCR since men with an undetectable postoperative USPSA are at significantly decreased risk of BCR. However the benefit of adjuvant therapy in this group as well as the implementation of genetics assays such as Prolaris and Decipher needs further investigation. 25 Finally, the optimal cutoff of USPSA is still unknown, and a lower USPSA threshold could increase the risk of detecting a clinically meaningless PSA rise.
Our prediction model can be used to schedule men for further diagnostics, for example, by PSMA-PET scanning for the detection of the anatomical location of the recurrence rather than proceeding to salvage radiotherapy of the prostatic fossa. Moreover, the model may help to plan men for salvage RT. Early salvage RT was associated with increased local toxicity; therefore, a predictor to reliably postpone before the PSA rises over 0.5 ng/mL is of value. 29 
| LI M ITATI O N S
Limitations of our study include the retrospective setting, the relatively short follow-up, and the selection bias due to a single-institution case series. The relative high BCR of 48% could be attributed to the study design which included only patients with postoperative PSA >0.01 ng/mL. Finally, although BCR is a clinically relevant end-point, only 18%-34% of patients ultimately develop systemic progression and metastatic disease. 6 Future studies could explore the association between USPSA and other end-points such as disease-specific and overall mortality. Validation of our predictor in larger patients' populations in other institutes is needed.
| CON CLUS ION
Ultrasensitive PSA after RARP is a useful prognostic indicator of 
